Current status of clinical trials assessing oncolytic virus therapy for urological cancers (Q38741837)

6 September 2017

Current status of clinical trials assessing oncolytic virus therapy for urological cancers (English)

1 reference

6 September 2017

1 reference

3

Yukio Homma

1 reference

6 September 2017

2

Hiroshi Fukuhara

1 reference

6 September 2017

Satoru Taguchi

1

1 reference

PubMed ID

28326624

6 September 2017

Tomoki Todo

series ordinal

4

1 reference

6 September 2017

21 March 2017

1 reference

International Journal of Urology

6 September 2017

1 reference

6 September 2017

24

1 reference

6 September 2017

342-351

1 reference

6 September 2017

5

1 reference

Oncolytic virus therapy for prostate cancer

6 September 2017

1 reference

Oncolytic virus therapy: A new era of cancer treatment at dawn

21 January 2018

1 reference

21 January 2018

Oncolytic virotherapy

1 reference

ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents

21 January 2018

1 reference

China approves world's first oncolytic virus therapy for cancer treatment

21 January 2018

1 reference

Interview with Robert Coffin, inventor of T-VEC: the first oncolytic immunotherapy approved for the treatment of cancer

21 January 2018

1 reference

Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma

21 January 2018

1 reference

Virus therapy for bladder cancer

21 January 2018

1 reference

Oncolytic viruses in the treatment of bladder cancer

21 January 2018

1 reference

Oncolytic virotherapy for renal cell carcinoma: a novel treatment paradigm?

21 January 2018

1 reference

Emerging agents for the therapy of advanced prostate cancer

21 January 2018

1 reference

Chapter eight--Oncolytic adenoviruses for cancer immunotherapy: data from mice, hamsters, and humans

21 January 2018

1 reference

A phase I trial of intravenous CG7870, a replication-selective, prostate-specific antigen-targeted oncolytic adenovirus, for the treatment of hormone-refractory, metastatic prostate cancer.

21 January 2018

1 reference

Suicide gene therapy in cancer: where do we stand now?

21 January 2018

1 reference

Viral based gene therapy for prostate cancer

21 January 2018

1 reference

A novel three-pronged approach to kill cancer cells selectively: concomitant viral, double suicide gene, and radiotherapy

21 January 2018

1 reference

Five-year follow-up of trial of replication-competent adenovirus-mediated suicide gene therapy for treatment of prostate cancer

21 January 2018

1 reference

Phase I trial of replication-competent adenovirus-mediated suicide gene therapy combined with IMRT for prostate cancer

21 January 2018

1 reference

Prostate cancer gene therapy clinical trials

21 January 2018

1 reference

Oncolytic herpes simplex virus engineering and preparation

21 January 2018

1 reference

Genetically Engineered Herpes Simplex Viral Vectors in the Treatment of Brain Tumors: A Review

21 January 2018

1 reference

Complete DNA sequence of the short repeat region in the genome of herpes simplex virus type 1.

21 January 2018

1 reference

The complete DNA sequence of the long unique region in the genome of herpes simplex virus type 1.

21 January 2018

1 reference

The function of herpes simplex virus genes: a primer for genetic engineering of novel vectors

21 January 2018

1 reference

Development and application of herpes simplex virus vectors for human gene therapy

21 January 2018

1 reference

Experimental Therapy of Human Glioma by Means of a Genetically Engineered Virus Mutant

21 January 2018

1 reference

Oncolytic herpes virus with defective ICP6 specifically replicates in quiescent cells with homozygous genetic mutations in p16.

21 January 2018

1 reference

Oncolytic HSV-1 virotherapy: clinical experience and opportunities for progress

21 January 2018

1 reference

ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties

21 January 2018

1 reference

Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas

21 January 2018

1 reference

Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial

21 January 2018

1 reference

A phase 1 trial of oncolytic HSV-1, G207, given in combination with radiation for recurrent GBM demonstrates safety and radiographic responses.

21 January 2018

1 reference

Oncolytic herpes simplex virus vector with enhanced MHC class I presentation and tumor cell killing.

21 January 2018

1 reference

A viral inhibitor of peptide transporters for antigen presentation

21 January 2018

1 reference

A cytosolic herpes simplex virus protein inhibits antigen presentation to CD8+ T lymphocytes

21 January 2018

1 reference

Intracarotid delivery of oncolytic HSV vector G47Delta to metastatic breast cancer in the brain.

21 January 2018

1 reference

Oncolytic herpes simplex virus vector therapy of breast cancer in C3(1)/SV40 T-antigen transgenic mice.

21 January 2018

1 reference

Triple gene-deleted oncolytic herpes simplex virus vector double-armed with interleukin 18 and soluble B7-1 constructed by bacterial artificial chromosome-mediated system

21 January 2018

1 reference

Oncolytic herpes simplex virus vector g47delta in combination with androgen ablation for the treatment of human prostate adenocarcinoma

21 January 2018

1 reference

Treatment of schwannomas with an oncolytic recombinant herpes simplex virus in murine models of neurofibromatosis type 2.

21 January 2018

1 reference

Treatment of implantable NF2 schwannoma tumor models with oncolytic herpes simplex virus G47Delta.

21 January 2018

1 reference

Analysis of genetically engineered oncolytic herpes simplex viruses in human prostate cancer organotypic cultures.

21 January 2018

1 reference

Anti-tumor effect of oncolytic herpes simplex virus G47delta on human nasopharyngeal carcinoma.

21 January 2018

1 reference

Treatment of human hepatocellular carcinoma by the oncolytic herpes simplex virus G47delta

21 January 2018

1 reference

The molecular basis of viral oncolysis: usurpation of the Ras signaling pathway by reovirus

21 January 2018

1 reference

Reovirus therapy of tumors with activated Ras pathway

21 January 2018

1 reference

A phase I study of intravenous oncolytic reovirus type 3 Dearing in patients with advanced cancer

21 January 2018

1 reference

Phase I study of a vaccine using recombinant vaccinia virus expressing PSA (rV-PSA) in patients with metastatic androgen-independent prostate cancer

21 January 2018

1 reference

Phase II randomized study of vaccine treatment of advanced prostate cancer (E7897): a trial of the Eastern Cooperative Oncology Group.

21 January 2018

1 reference

A phase I trial of pox PSA vaccines (PROSTVAC-VF) with B7-1, ICAM-1, and LFA-3 co-stimulatory molecules (TRICOM) in patients with prostate cancer

21 January 2018

1 reference

Phase I study of intraprostatic vaccine administration in men with locally recurrent or progressive prostate cancer.

21 January 2018

1 reference

A New Sendai Virus Vector Deficient in the Matrix Gene Does Not Form Virus Particles and Shows Extensive Cell-to-Cell Spreading

21 January 2018

1 reference

Efficient eradication of hormone-resistant human prostate cancers by inactivated Sendai virus particle

21 January 2018

1 reference

Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study

21 January 2018

1 reference

Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer

21 January 2018

1 reference

Intravesical treatments of bladder cancer: review.

21 January 2018

1 reference

CG0070, a conditionally replicating granulocyte macrophage colony-stimulating factor--armed oncolytic adenovirus for the treatment of bladder cancer

21 January 2018

1 reference

Transcription of the E2F-1 gene is rendered cell cycle dependent by E2F DNA-binding sites within its promoter

21 January 2018

1 reference

Retinoblastoma gene mutations in primary human bladder cancer

21 January 2018

1 reference

21 January 2018

1 reference

Treatment of metastatic renal cell carcinoma.

21 January 2018

1 reference

Treatment and overall survival in renal cell carcinoma: a Swedish population-based study (2000-2008).

21 January 2018

1 reference

A Systematic Review of Immunotherapy in Urologic Cancer: Evolving Roles for Targeting of CTLA-4, PD-1/PD-L1, and HLA-G.

21 January 2018

1 reference

Cross-trial analysis of immunologic and clinical data resulting from phase I and II trials of MVA-5T4 (TroVax) in colorectal, renal, and prostate cancer patients

21 January 2018

1 reference

Clinical trial of attenuated vaccinia virus AS strain in the treatment of advanced adenocarcinoma. Report on two cases

21 January 2018

1 reference

Systemic armed oncolytic and immunologic therapy for cancer with JX-594, a targeted poxvirus expressing GM-CSF.

21 January 2018

1 reference

The oncolytic poxvirus JX-594 selectively replicates in and destroys cancer cells driven by genetic pathways commonly activated in cancers

21 January 2018

1 reference

Intratumoral recombinant GM-CSF-encoding virus as gene therapy in patients with cutaneous melanoma

21 January 2018

1 reference

Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial

21 January 2018

1 reference

Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans

21 January 2018

1 reference

Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer

21 January 2018

1 reference

Phase 1 study of intratumoral Pexa-Vec (JX-594), an oncolytic and immunotherapeutic vaccinia virus, in pediatric cancer patients

21 January 2018

1 reference

Phase 1b Trial of Biweekly Intravenous Pexa-Vec (JX-594), an Oncolytic and Immunotherapeutic Vaccinia Virus in Colorectal Cancer

21 January 2018

1 reference

The emerging therapeutic potential of the oncolytic immunotherapeutic Pexa-Vec (JX-594)

21 January 2018

1 reference

Scientific interest in Newcastle disease virus is reviving

21 January 2018

1 reference

Adjuvant treatment of locally advanced renal cancer with autologous virus-modified tumor vaccines

21 January 2018

1 reference

Phase I trial of intravenous administration of PV701, an oncolytic virus, in patients with advanced solid cancers

21 January 2018

1 reference

A phase 1 clinical study of intravenous administration of PV701, an oncolytic virus, using two-step desensitization

21 January 2018

1 reference

Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1111/IJU.13325

1 reference

6 September 2017

1 reference

PubMed ID

28326624